{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:01Z","timestamp":1792783261737,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tekirdag Nam\u0131k Kemal University","id":[{"id":"https:\/\/ror.org\/01a0mk874","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as cornerstone therapies for heart failure with reduced ejection fraction (HFrEF), owing to their cardioprotective and hematologic effects. While their impact on hemoglobin and hematocrit levels is increasingly recognized, the influence of SGLT2 inhibitors on mean platelet volume (MPV), a surrogate marker of platelet activation and cardiovascular risk, remains underexplored in HFrEF patients. While SGLT2 inhibitors\u2019 effects on MPV have been studied in DM, this is the first study examining MPV changes specifically in HFrEF patients with adjustment for diuretic therapy. This retrospective study included 80 HFrEF patients receiving guideline-directed medical therapy to which SGLT2 inhibitors were subsequently added. Baseline and 6-month follow-up data on hematological and biochemical parameters were collected. Exclusion criteria included active infection, malignancy, advanced renal failure, hematologic disorders, and recent transfusions. MPV and platelet counts were analyzed using standardized protocols and equipment. Following 6\u00a0months of SGLT2 inhibitor therapy, MPV values decreased significantly (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05), while platelet counts increased significantly (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Although hemoglobin and hematocrit levels showed upward trends, these changes were not statistically significant. No significant correlation was observed between \u0394MPV and \u0394PLT. Other biochemical markers remained stable throughout the study period. SGLT2 inhibitor therapy was associated with a significant reduction in MPV and an increase in platelet count among patients with HFrEF. These hematological changes may represent an additional mechanism by which SGLT2 inhibitors exert cardiovascular benefit. However, prospective, randomized trials are needed to validate these findings and explore the clinical significance of MPV modulation in heart failure management.\n                  <\/jats:p>","DOI":"10.1007\/s11739-026-04398-8","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:23:08Z","timestamp":1782192188000},"page":"2133-2139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of SGLT2 inhibitors on mean platelet volume in heart failure with reduced ejection fraction: a real-world analysis independent of diuretic therapy"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-6411","authenticated-orcid":false,"given":"H\u00fcseyin","family":"Orta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1401-5727","authenticated-orcid":false,"given":"Cihan","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8322-3514","authenticated-orcid":false,"given":"Aykut","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6551-2234","authenticated-orcid":false,"given":"Ferhat","family":"Perk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3304-4125","authenticated-orcid":false,"given":"Aydin","family":"Akyuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"36","key":"4398_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"5","key":"4398_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M (2009) Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85(5):513\u2013519","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"4398_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16162965","volume":"16","author":"A Tentolouris","year":"2019","unstructured":"Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N (2019) SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health 16(16):2965","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"4398_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0491-5","volume":"16","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A et al (2017) Dapagliflozin decreases small dense low-density lipoprotein cholesterol and increases high-density lipoprotein 2 cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol 16(1):8","journal-title":"Cardiovasc Diabetol"},{"key":"4398_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117236","volume":"394","author":"LE Bechmann","year":"2024","unstructured":"Bechmann LE, Emanuelsson F, Nordestgaard BG, Benn M (2024) SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis 394:117236","journal-title":"Atherosclerosis"},{"issue":"2","key":"4398_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102702","volume":"17","author":"P Ekanayake","year":"2023","unstructured":"Ekanayake P, Mudaliar S (2023) Increase in hematocrit with SGLT-2 inhibitors: hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia? Diabetes Metab Syndr Clin Res Rev 17(2):102702","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"2","key":"4398_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/00001721-199603000-00011","volume":"7","author":"PM Bath","year":"1996","unstructured":"Bath PM, Butterworth RJ (1996) Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 7(2):157\u2013161","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"4398_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1046\/j.1365-2141.2002.03441.x","volume":"117","author":"G Endler","year":"2002","unstructured":"Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C et al (2002) Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 117(2):399\u2013404","journal-title":"Br J Haematol"},{"issue":"1","key":"4398_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1538-7836.2010.04110.x","volume":"9","author":"J Klovaite","year":"2011","unstructured":"Klovaite J, Benn M, Yazdanyar S, Nordestgaard BG (2011) High platelet volume and increased risk of myocardial infarction: 39,531 participants from the general population. J Thromb Haemost 9(1):49\u201356","journal-title":"J Thromb Haemost"},{"issue":"4","key":"4398_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041818","volume":"105","author":"QC Wang","year":"2026","unstructured":"Wang QC, Chen Y, Guan CL, Lu WK (2026) Mean platelet volume and cardiovascular outcomes in patients with coronary heart disease: a meta-analysis of prospective studies. Medicine (Baltimore) 105(4):e41818","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"4398_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.62347\/XUXB3631","volume":"15","author":"AP Abhari","year":"2025","unstructured":"Abhari AP, Adelparvar F, Rezvanian P, Meraji Far F, Bakhshi R, Qorbani F, Heidarpour M, Mozafari AM, Shafie D, Movahed MR (2025) Prognostic value of platelet volume indices in heart failure: a systematic review and meta-analysis. Am J Blood Res 15(4):61\u201379","journal-title":"Am J Blood Res"},{"key":"4398_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin, a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853\u2013862","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"4398_CR13","first-page":"291","volume":"45","author":"MA Eren","year":"2019","unstructured":"Eren MA, Cindoglu C, Gokce BD, Gokce A, Sabuncu T (2019) Effects of dapagliflozin treatment on platelet functions and inflammation in patients with type 2 diabetes. Uludag Med J 45(3):291\u2013294","journal-title":"Uludag Med J"},{"issue":"8","key":"4398_CR14","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1007\/s00125-021-05498-0","volume":"64","author":"C Kohlmorgen","year":"2021","unstructured":"Kohlmorgen C, Gerfer S, Feldmann K, Twarock S, Hartwig S, Lehr S et al (2021) Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Diabetologia 64(8):1834\u20131849","journal-title":"Diabetologia"},{"issue":"1","key":"4398_CR15","first-page":"140","volume":"6","author":"P Akhanli","year":"2023","unstructured":"Akhanli P, Hepsen S, Kizilgul M, Bilen Ayhan S, Duger H et al (2023) The impact of SGLT2 inhibitor therapy on platelet function in type 2 diabetes mellitus. J Health Sci Med 6(1):140\u2013144","journal-title":"J Health Sci Med"},{"key":"4398_CR16","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S (2019) Possible mechanism of hematocrit elevation by sodium\u2013glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139:1985\u20131987","journal-title":"Circulation"},{"issue":"2","key":"4398_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/0003319715584725","volume":"67","author":"A Akyuz","year":"2016","unstructured":"Akyuz A, Akkoyun DC, Degirmenci H, Oran M (2016) Rosuvastatin decreases mean platelet volume in patients with diabetes mellitus. Angiology 67(2):116\u2013120","journal-title":"Angiology"},{"issue":"4","key":"4398_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00392-021-01913-z","volume":"111","author":"T Tager","year":"2022","unstructured":"Tager T, Frankenstein L, Atar D, Agewall S, Frey N, Grundtvig M et al (2022) Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clin Res Cardiol 111(4):428\u2013439","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"4398_CR19","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1161\/01.HYP.25.5.1096","volume":"25","author":"SE Kjeldsen","year":"1995","unstructured":"Kjeldsen SE, Weder AB, Egan B, Neubig R, Zweifler AJ, Julius S (1995) Effect of circulating epinephrine on platelet function and hematocrit. Hypertension 25(5):1096\u20131105","journal-title":"Hypertension"},{"issue":"2","key":"4398_CR20","first-page":"260","volume":"14","author":"A Catana","year":"2024","unstructured":"Catana A, Andrei CL, Guberna S, Ceban O, Sinescu CJ (2024) Possible correlations between mean platelet volume and biological, electrocardiographic, and echocardiographic parameters in patients with heart failure. Life (Basel) 14(2):260","journal-title":"Life (Basel)"},{"issue":"6","key":"4398_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/ageing\/afg113","volume":"32","author":"VL Crawford","year":"2003","unstructured":"Crawford VL, McNerlan SE, Stout RW (2003) Seasonal changes in platelets, fibrinogen and factor VII in elderly people. Age Ageing 32(6):661\u2013665","journal-title":"Age Ageing"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04398-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04398-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04398-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:34:55Z","timestamp":1789540495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04398-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4398"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04398-8","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval to conduct the study was received from the Non-Interventional Clinical Research Ethics Committee of Tekirdag Namik Kemal University Faculty of Medicine.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. No animals were involved in this study.","order":3,"name":"Ethics","label":"Human and animal rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective nature of the study, the requirement for informed consent was waived by the Non-Interventional Clinical Research Ethics Committee of Tekirdag Namik Kemal University Faculty of Medicine.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}